AU2022217160A1 - Topical ophthalmological compositions - Google Patents

Topical ophthalmological compositions Download PDF

Info

Publication number
AU2022217160A1
AU2022217160A1 AU2022217160A AU2022217160A AU2022217160A1 AU 2022217160 A1 AU2022217160 A1 AU 2022217160A1 AU 2022217160 A AU2022217160 A AU 2022217160A AU 2022217160 A AU2022217160 A AU 2022217160A AU 2022217160 A1 AU2022217160 A1 AU 2022217160A1
Authority
AU
Australia
Prior art keywords
topical ophthalmological
ophthalmological composition
atropine
topical
mct
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022217160A
Other languages
English (en)
Other versions
AU2022217160A9 (en
Inventor
Van DINH
Jinsong Ni
Rong Yang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ADS Therapeutics LLC
Original Assignee
ADS Therapeutics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ADS Therapeutics LLC filed Critical ADS Therapeutics LLC
Publication of AU2022217160A1 publication Critical patent/AU2022217160A1/en
Publication of AU2022217160A9 publication Critical patent/AU2022217160A9/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2022217160A 2021-02-03 2022-02-02 Topical ophthalmological compositions Pending AU2022217160A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163145091P 2021-02-03 2021-02-03
US63/145,091 2021-02-03
PCT/US2022/014811 WO2022169788A1 (en) 2021-02-03 2022-02-02 Topical ophthalmological compositions

Publications (2)

Publication Number Publication Date
AU2022217160A1 true AU2022217160A1 (en) 2023-08-17
AU2022217160A9 AU2022217160A9 (en) 2025-01-30

Family

ID=82741579

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022217160A Pending AU2022217160A1 (en) 2021-02-03 2022-02-02 Topical ophthalmological compositions

Country Status (8)

Country Link
US (3) US12070501B1 (cg-RX-API-DMAC7.html)
EP (1) EP4288151A4 (cg-RX-API-DMAC7.html)
JP (2) JP7749020B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230142548A (cg-RX-API-DMAC7.html)
AU (1) AU2022217160A1 (cg-RX-API-DMAC7.html)
CA (1) CA3206612A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023009091A (cg-RX-API-DMAC7.html)
WO (1) WO2022169788A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL268457B (en) * 2019-08-04 2022-05-01 Omega 3 Galilee Ltd Oil- suspension of edible solids and methods of preparing the same
US11191751B1 (en) * 2020-10-08 2021-12-07 Ads Therapeutics Llc Topical ophthalmological atropine free base compositions
WO2025034554A1 (en) * 2023-08-04 2025-02-13 Ads Therapeutics Llc Compositions and methods for delivery of ophthalmological actives
WO2025131038A1 (en) * 2023-12-21 2025-06-26 Ads Therapeutics Llc Compositions and methods for delivery of pharmaceutical actives
WO2025259674A1 (en) * 2024-06-11 2025-12-18 Ads Therapeutics Llc Compositions and methods for delivery of pharmaceutical actives
WO2026003129A1 (en) * 2024-06-26 2026-01-02 Novaliq Gmbh Stabilization of (r)-ruxolitinib

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19536504C2 (de) 1995-09-29 1999-09-23 H Meinert Verwendung fluorierter Alkane
DE10030378A1 (de) 2000-06-21 2002-03-14 Audit Inst For Medical Service Neue pharmazeutische Zusammensetzung zur topischen Anwendung von wasserunlöslichen und/oder schwer wasserlöslichen Wirkstoffen
CN101049287A (zh) 2006-04-07 2007-10-10 财团法人长庚纪念医院 抑制近视度数增加的低浓度阿托平眼药剂及其制造方法
US20070254914A1 (en) 2006-05-01 2007-11-01 Non-Profit Organization Chang Gung Memorial Hospital Low-concentration atropine solution for preventing myopia progression and preparing method thereof
US20100323978A1 (en) * 2009-06-22 2010-12-23 Calvin Hanna Non-aqueous oil delivery system for ophthalmic drugs
ES2564502T3 (es) 2010-03-17 2016-03-23 Novaliq Gmbh Composición farmacéutica para el tratamiento de la presión intraocular aumentada
EP2462921A1 (en) 2010-11-11 2012-06-13 Novaliq GmbH Liquid pharmaceutical compositions for the treatment of a posterior eye disease
WO2012161655A1 (en) 2011-05-23 2012-11-29 Singapore Health Services Pte Ltd Composition and/or method for reducing and/or preventing myopia progression comprising atropine
CN102526051A (zh) * 2012-03-09 2012-07-04 哈尔滨医科大学 一种治疗真菌性角膜炎的眼药膏
EP2895144B1 (en) 2012-09-12 2017-01-11 Novaliq GmbH Semifluorinated alkane compositions
MX363182B (es) * 2012-09-12 2019-03-13 Novaliq Gmbh Composiciones que comprenden mezclas de alcanos semifluorados.
EP2783703A1 (en) 2013-03-25 2014-10-01 B. Braun Melsungen AG Semifluorocarbon compound containing contrast agent
US9421199B2 (en) * 2014-06-24 2016-08-23 Sydnexis, Inc. Ophthalmic composition
WO2016172712A2 (en) * 2015-04-23 2016-10-27 Sydnexis, Inc. Ophthalmic composition
KR20170120161A (ko) * 2015-03-05 2017-10-30 알러간, 인코포레이티드 안과용 약물 전달을 위한 자가-유화 약물 전달 시스템(sedds)
CN109803650A (zh) 2016-09-28 2019-05-24 诺瓦利克有限责任公司 包含大麻素受体结合配体的组合物
WO2018064354A1 (en) 2016-09-28 2018-04-05 Medicon Pharmaceuticals, Inc. Compositions and methods for treating ophthalmic conditions
WO2018114557A1 (en) 2016-12-22 2018-06-28 Novaliq Gmbh Compositions comprising tacrolimus for the treatment of intraocular inflammatory eye diseases
EP3585386A4 (en) 2017-02-21 2020-12-30 Singapore Health Services PTE Ltd COMPOSITION AND PROCESS FOR PREVENTING OR DELAYING THE ONCE OF MYOPIA INCLUDING ATROPINE
EP3638643B1 (en) 2017-06-12 2023-01-18 Novaliq GmbH Process for the preparation of semifluorinated alkanes using grignard reagents
JP7814839B2 (ja) 2017-09-27 2026-02-17 ノバリック ゲーエムベーハー 眼疾患の治療に使用するためのラタノプロストを含む眼科用組成物
CN111182893A (zh) 2017-10-04 2020-05-19 诺瓦利克有限责任公司 包含f6h8的眼用组合物
CA3112031A1 (en) 2018-10-12 2020-04-16 Novaliq Gmbh Ophthalmic composition for treatment of dry eye disease
CN113518619A (zh) 2019-01-21 2021-10-19 诺瓦利克有限责任公司 用于治疗眼部新生血管形成的药物组合物
AU2020216470B2 (en) * 2019-02-01 2023-05-04 Alcon Inc. Compounds, compositions and methods for treatment of myopia
US11191751B1 (en) 2020-10-08 2021-12-07 Ads Therapeutics Llc Topical ophthalmological atropine free base compositions

Also Published As

Publication number Publication date
EP4288151A4 (en) 2025-01-01
US20260124305A1 (en) 2026-05-07
KR20230142548A (ko) 2023-10-11
JP2025176201A (ja) 2025-12-03
US20250000980A1 (en) 2025-01-02
EP4288151A1 (en) 2023-12-13
CA3206612A1 (en) 2022-08-11
MX2023009091A (es) 2023-08-09
JP7749020B2 (ja) 2025-10-03
JP2024511695A (ja) 2024-03-15
WO2022169788A1 (en) 2022-08-11
US12485177B2 (en) 2025-12-02
AU2022217160A9 (en) 2025-01-30
US12070501B1 (en) 2024-08-27

Similar Documents

Publication Publication Date Title
US12485177B2 (en) Topical ophthalmological compositions
EP4225284B1 (en) Topical ophthalmological compositions
JP7353292B2 (ja) ネビボロールを含む医薬組成物
CN111867560B (zh) 包含噻吗洛尔的药物组合物
SG11202107259QA (en) Formulations of 4-(7-hydroxy-2-isopropyl-4-oxo-4h-quinazolin-3-yl)-benzonitrile
CN119789854A (zh) 用于递送眼科活性物的组合物和方法
Okka et al. Effects of latrunculin B on outflow facility, intraocular pressure, corneal thickness, and miotic and accommodative responses to pilocarpine in monkeys
Vale et al. Drugs and the Eye: Sponsored by the British Optical Association
CN112294761A (zh) 一种难溶性药物的眼用胶束制剂
CN120093684A (zh) 局部眼科组合物
EP0205606B1 (en) Pharmaceutical compositions and their use as mydriatics
HK40086649A (zh) 局部眼科组合物
CN120732828A (zh) 一种含有ar-15512的组合物及其制备方法和应用
HK40044057A (en) Pharmaceutical compositions comprising nebivolol
HK40044057B (en) Pharmaceutical compositions comprising nebivolol
JPH06511014A (ja) 眼への投与に用いる、緩衝剤系を含有するベラパミル塩酸製剤などの眼科用液剤

Legal Events

Date Code Title Description
SREP Specification republished